Addressing COVID-19 Immune Storm: A Way Forward
COVID-19 a global pandemic is a cause for panic due to the increasing numbers and the associated fatality rate of ~5%. Death due to COVID-19 is ascribed majorly to the cytokine storm a hyper immune reaction that results in acute respiratory distress syndrome. Following the WHO Solidarity initiative, a large number of clinical trials approved at breakneck speed across the globe. It is encouraging to note that almost all trials are addressing both antiviral effect and lung protection. Clinical trials with a focus on decreasing mortality indeed harbinger a positive trend, as the world waits expectantly for a solution to this dreaded COVID-19 pandemic.
Keywords:Clinical trials, COVID-19, Cytokine storm, Immunomodulation, SARS-CoV-2
“WHO,” WHO Coronavirus Disease (COVID-19) Dashboard, Jun. 30, 2020. https://covid19.who.int/?gclid=EAIaIQobChMIleGg_tKp6gIVCB4rCh26ggk4EAAYASAAEgKEhvD_BwE (accessed Jun. 08, 2020).
J. Amir Singh, “COVID-19: Science and global health governance under attack,” SAMJ: South African Medical Journal, vol. 110, no. 6, pp. 1–2, 2020.
Y. Jamilloux et al., “Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions,” Autoimmunity Reviews, p. 102567, 2020.
X. Cao, “COVID-19: immunopathology and its implications for therapy,” Nature Reviews Immunology, vol. 20, no. 5, Art. no. 5, May 2020, doi: 10.1038/s41577-020-0308-3.
R. J. Jose and A. Manuel, “COVID-19 cytokine storm: the interplay between inflammation and coagulation,” The Lancet Respiratory Medicine, vol. 8, no. 6, pp. e46–e47, Jun. 2020, doi: 10.1016/S2213-2600(20)30216-2.
V. J. Costela-Ruiz, R. Illescas-Montes, J. M. Puerta-Puerta, C. Ruiz, and L. Melguizo-Rodríguez, “SARS-CoV-2 infection: The role of cytokines in COVID-19 disease,” Cytokine Growth Factor Rev, Jun. 2020, doi: 10.1016/j.cytogfr.2020.06.001.
L. A. Henderson et al., “On the alert for cytokine storm: Immunopathology in COVID-19,” Arthritis & Rheumatology, 2020.
N. Mangalmurti and C. A. Hunter, “Cytokine Storms: Understanding COVID-19,” Immunity, 2020.
N. Vabret et al., “Immunology of COVID-19: Current State of the Science,” Immunity, vol. 52, no. 6, pp. 910–941, Jun. 2020, doi: 10.1016/j.immuni.2020.05.002.
S. H. Nile, A. Nile, J. Qiu, L. Li, X. Jia, and G. Kai, “COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons,” Cytokine & Growth Factor Reviews, 2020.
F. Zeng, Y. Guo, M. Yin, X. Chen, and G. Deng, “Association of inflammatory markers with the severity of COVID-19,” medRxiv, 2020.
R. K. Guy, R. S. DiPaola, F. Romanelli, and R. E. Dutch, “Rapid repurposing of drugs for COVID-19,” Science, vol. 368, no. 6493, pp. 829–830, 2020.
S. L. Senanayake, Drug repurposing strategies for COVID-19. Future Science, 2020.
C. Huang et al., “Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China,” The lancet, vol. 395, no. 10223, pp. 497–506, 2020.
T. M. C. de Lucena, A. F. da Silva Santos, B. R. de Lima Fabrício, M. E. de Albuquerque Borborema, and J. de Azevêdo Silva, “Mechanism of inflammatory response in associated comorbidities in COVID-19,” Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020.
K. Kupferschmidt and J. Cohen, Race to find COVID-19 treatments accelerates. American Association for the Advancement of Science, 2020.
Z. Jin, J.-Y. Liu, R. Feng, L. Ji, Z.-L. Jin, and H.-B. Li, “Drug treatment of coronavirus disease 2019 (COVID-19) in China.,” European Journal of Pharmacology, p. 173326, Jun. 2020, doi: 10.1016/j.ejphar.2020.173326.
U. Sandkovsky, P. Colley, T. Sam, A. M. Modrykamien, and M. Berhe, “The dynamic treatment of SARS-CoV-2 disease,” Baylor University Medical Center Proceedings, pp. 1–8, Jun. 2020, doi: 10.1080/08998280.2020.1780086.
J. Hadjadj et al., “Impaired type I interferon activity and exacerbated inflammatory responses in severe Covid-19 patients,” MedRxiv, 2020.
D. E. Gordon et al., “A SARS-CoV-2 protein interaction map reveals targets for drug repurposing,” Nature, pp. 1–13, 2020.
J. Rehwinkel and M. U. Gack, “RIG-I-like receptors: their regulation and roles in RNA sensing,” Nature Reviews Immunology, pp. 1–15, 2020.
B. Diao et al., “Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19),” Frontiers in Immunology, vol. 11, p. 827, 2020.
C. Moon, Fighting COVID-19 exhausts T cells. Nature Publishing Group, 2020.
F. Venet, C.-S. Chung, X. Huang, J. Lomas-Neira, Y. Chen, and A. Ayala, “Lymphocytes in the Development of Lung Inflammation: A Role for Regulatory CD4+ T Cells in Indirect Pulmonary Lung Injury,” J Immunol, vol. 183, no. 5, pp. 3472–3480, Sep. 2009, doi: 10.4049/jimmunol.0804119.
K. Yuki, M. Fujiogi, and S. Koutsogiannaki, “COVID-19 pathophysiology: A review,” Clin Immunol, vol. 215, p. 108427, Jun. 2020, doi: 10.1016/j.clim.2020.108427.
H. Zhang, J. M. Penninger, Y. Li, N. Zhong, and A. S. Slutsky, “Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target,” Intensive care medicine, vol. 46, no. 4, pp. 586–590, 2020.
M. Hoffmann et al., “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor,” Cell, 2020.
L. Samavati and B. D. Uhal, “ACE2, Much More Than Just a Receptor for SARS-COV-2,” Frontiers in Cellular and Infection Microbiology, vol. 10, p. 317, 2020.
M. Benucci, A. Damiani, M. Infantino, M. Manfredi, and L. Quartuccio, “Old and new antirheumatic drugs for the treatment of COVID-19,” Joint Bone Spine, vol. 87, no. 3, p. 195, 2020.
X. Xu et al., “Effective treatment of severe COVID-19 patients with tocilizumab,” Proceedings of the National Academy of Sciences, vol. 117, no. 20, pp. 10970–10975, 2020.
H. Bian et al., “Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial,” MedRxiv, 2020.
B. Liu, M. Li, Z. Zhou, X. Guan, and Y. Xiang, “Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?” Journal of Autoimmunity, p. 102452, 2020.
B. Russell et al., “Associations between immune-suppressive and stimulating drugs and novel COVID-19—a systematic review of current evidence,” ecancermedicalscience, vol. 14, 2020.
G. Monteleone, P. C. Sarzi-Puttini, and S. Ardizzone, “Preventing COVID-19-induced pneumonia with anticytokine therapy,” The Lancet Rheumatology, vol. 2, no. 5, pp. e255–e256, 2020.
G. Giovannoni, “Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19,” Multiple Sclerosis and Related Disorders, 2020.
E. G. Favalli and R. Caporali, “GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?” The Lancet Rheumatology, 2020.
T. P. Velavan and C. G. Meyer, “The COVID-19 epidemic,” Tropical medicine & international health, vol. 25, no. 3, p. 278, 2020.
F. Diurno et al., “Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.,” European review for medical and pharmacological sciences, vol. 24, no. 7, pp. 4040–4047, 2020.
S. G. V. Rosa and W. C. Santos, “Clinical trials on drug repositioning for COVID-19 treatment,” Revista Panamericana de Salud Pública, vol. 44, p. e40, 2020.
A. Golchin, E. Seyedjafari, and A. Ardeshirylajimi, “Mesenchymal stem cell therapy for COVID-19: present or future,” Stem cell reviews and reports, pp. 1–7, 2020.
P. P. Roudsari et al., “Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19,” Cell and Tissue Banking, pp. 1–21, 2020.
B. Chitra, P. S. Surinder, and C. Sangeeta, “Can Mesenchymal Stem Cell Therapy Be the Interim Management of COVID-19?” Drug discoveries & therapeutics.
F. Dastan et al., “Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces,” Iranian Journal of Pharmaceutical Research, vol. 19, no. 1, pp. 1–2, 2020.
K.-H. Chen et al., “Pharmacological development of the potential adjuvant therapeutic agents against coronavirus disease 2019,” Journal of the Chinese Medical Association, 2020.
C. Bosteels et al., “Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial,” Trials, vol. 21, no. 1, pp. 1–2, 2020.
F. J. R. Paumgartten, I. F. Delgado, L. da Rocha Pitta, and A. C. A. X. de Oliveira, “Drug repurposing clinical trials in the search for life-saving Covid-19 therapies; research targets and methodological and ethical issues,” Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia, 2020.
A. Pandey et al., “Potential therapeutic targets for combating SARS-CoV-2: Drug repurposing, clinical trials and recent advancements,” Life Sciences, p. 117883, 2020.
R.-R. Tian et al., “CD24Fc protects against viral pneumonia in simian immunodeficiency virus-infected Chinese rhesus monkeys,” Cellular & Molecular Immunology, pp. 1–2, 2020.
P. R. Martins-Filho, J. A. Barreto-Alves, and R. Fakhouri, “Potential role for nitazoxanide in treating SARS-CoV-2 infection,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 319, no. 1, pp. L35–L36, 2020.
D. Gupta, A. K. Sahoo, and A. Singh, “Ivermectin: potential candidate for the treatment of COVID-19,” The Brazilian Journal of Infectious Diseases, 2020.
N. Hossein-khannazer, B. Shokoohian, A. Shpichka, H. A. Aghdaei, P. Timashev, and M. Vosough, “Novel therapeutic approaches for treatment of COVID-19,” Journal of Molecular Medicine (Berlin, Germany), p. 1, 2020.
B. Russell, C. Moss, A. Rigg, and M. Van Hemelrijck, “COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?” ecancermedicalscience, vol. 14, 2020.
L. Zha et al., “Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19),” Medical Journal of Australia, vol. 212, no. 9, pp. 416–420, 2020.
M. Kermali, R. K. Khalsa, K. Pillai, Z. Ismail, and A. Harky, “The role of biomarkers in diagnosis of COVID-19–A systematic review,” Life Sciences, p. 117788, 2020.
Copyright (c) 2020 Amit Lokhande
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Any non-commercial use, distribution, adaptation, and reproduction in any medium is permitted as long as the original work is properly cited. However, caution and responsibility are required when reusing as the articles on the preprint server are not peer-reviewed. Readers are advised to check for the availability of any updated or peer-reviewed version.